Tags

Type your tag names separated by a space and hit enter

Proposed Mechanisms of Targeting COVID-19 by Delivering Mesenchymal Stem Cells and Their Exosomes to Damaged Organs.
Stem Cell Rev Rep. 2021 02; 17(1):176-192.SC

Abstract

With the outbreak of coronavirus disease (COVID-19) caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the world has been facing an unprecedented challenge. Considering the lack of appropriate therapy for COVID-19, it is crucial to develop effective treatments instead of supportive approaches. Mesenchymal stem cells (MSCs) as multipotent stromal cells have been shown to possess treating potency through inhibiting or modulating the pathological events in COVID-19. MSCs and their exosomes participate in immunomodulation by controlling cell-mediated immunity and cytokine release. Furthermore, they repair the renin-angiotensin-aldosterone system (RAAS) malfunction, increase alveolar fluid clearance, and reduce the chance of hypercoagulation. Besides the lung, which is the primary target of SARS-CoV-2, the heart, kidney, nervous system, and gastrointestinal tract are also affected by COVID-19. Thus, the efficacy of targeting these organs via different delivery routes of MSCs and their exosomes should be evaluated to ensure safe and effective MSCs administration in COVID-19. This review focuses on the proposed therapeutic mechanisms and delivery routes of MSCs and their exosomes to the damaged organs. It also discusses the possible application of primed and genetically modified MSCs as a promising drug delivery system in COVID-19. Moreover, the recent advances in the clinical trials of MSCs and MSCs-derived exosomes as one of the promising therapeutic approaches in COVID-19 have been reviewed.

Authors+Show Affiliations

Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran.Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran.Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. niknejad@sbmu.ac.ir.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

33432484

Citation

Jamshidi, Elham, et al. "Proposed Mechanisms of Targeting COVID-19 By Delivering Mesenchymal Stem Cells and Their Exosomes to Damaged Organs." Stem Cell Reviews and Reports, vol. 17, no. 1, 2021, pp. 176-192.
Jamshidi E, Babajani A, Soltani P, et al. Proposed Mechanisms of Targeting COVID-19 by Delivering Mesenchymal Stem Cells and Their Exosomes to Damaged Organs. Stem Cell Rev Rep. 2021;17(1):176-192.
Jamshidi, E., Babajani, A., Soltani, P., & Niknejad, H. (2021). Proposed Mechanisms of Targeting COVID-19 by Delivering Mesenchymal Stem Cells and Their Exosomes to Damaged Organs. Stem Cell Reviews and Reports, 17(1), 176-192. https://doi.org/10.1007/s12015-020-10109-3
Jamshidi E, et al. Proposed Mechanisms of Targeting COVID-19 By Delivering Mesenchymal Stem Cells and Their Exosomes to Damaged Organs. Stem Cell Rev Rep. 2021;17(1):176-192. PubMed PMID: 33432484.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Proposed Mechanisms of Targeting COVID-19 by Delivering Mesenchymal Stem Cells and Their Exosomes to Damaged Organs. AU - Jamshidi,Elham, AU - Babajani,Amirhesam, AU - Soltani,Pegah, AU - Niknejad,Hassan, Y1 - 2021/01/11/ PY - 2020/12/13/accepted PY - 2021/1/13/pubmed PY - 2021/3/3/medline PY - 2021/1/12/entrez KW - COVID-19 KW - RAAS KW - SARS-CoV-2 KW - clinical trials KW - cytokine storm KW - drug delivery KW - exosome KW - mesenchymal stem cells SP - 176 EP - 192 JF - Stem cell reviews and reports JO - Stem Cell Rev Rep VL - 17 IS - 1 N2 - With the outbreak of coronavirus disease (COVID-19) caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the world has been facing an unprecedented challenge. Considering the lack of appropriate therapy for COVID-19, it is crucial to develop effective treatments instead of supportive approaches. Mesenchymal stem cells (MSCs) as multipotent stromal cells have been shown to possess treating potency through inhibiting or modulating the pathological events in COVID-19. MSCs and their exosomes participate in immunomodulation by controlling cell-mediated immunity and cytokine release. Furthermore, they repair the renin-angiotensin-aldosterone system (RAAS) malfunction, increase alveolar fluid clearance, and reduce the chance of hypercoagulation. Besides the lung, which is the primary target of SARS-CoV-2, the heart, kidney, nervous system, and gastrointestinal tract are also affected by COVID-19. Thus, the efficacy of targeting these organs via different delivery routes of MSCs and their exosomes should be evaluated to ensure safe and effective MSCs administration in COVID-19. This review focuses on the proposed therapeutic mechanisms and delivery routes of MSCs and their exosomes to the damaged organs. It also discusses the possible application of primed and genetically modified MSCs as a promising drug delivery system in COVID-19. Moreover, the recent advances in the clinical trials of MSCs and MSCs-derived exosomes as one of the promising therapeutic approaches in COVID-19 have been reviewed. SN - 2629-3277 UR - https://www.unboundmedicine.com/medline/citation/33432484/Proposed_Mechanisms_of_Targeting_COVID_19_by_Delivering_Mesenchymal_Stem_Cells_and_Their_Exosomes_to_Damaged_Organs_ DB - PRIME DP - Unbound Medicine ER -